MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Chorea (also see specific diagnoses, Huntingtons disease, etc): Treatment"

  • 2025 International Congress

    Long-Term Safety and Efficacy of Valbenazine for Treating Huntington’s Disease Chorea

    E. Furr Stimming, E. Kayson, S. Karpuram, J. Goldstein, S. Hinton, O. Klepitskaya, H. Zhang, E. Dunayevich, D. Haubenberger (Houston, USA)

    Objective: To present safety and efficacy results from a long-term study of once-daily valbenazine for chorea associated with Huntington’s disease (HD). Background: In a 12-week…
  • 2025 International Congress

    Long-term results of pallidal deep brain stimulation in patients with Huntington’s disease

    A. Gamaleya, A. Poddubskaya, S. Asriyants, A. Tomskiy (Moscow, Russian Federation)

    Objective: To analyze long-term results of pallidal (GPi) deep brain stimulation (DBS) in patients with Huntington's disease (HD). Background: In HD, DBS is suggested to…
  • 2025 International Congress

    Analysis of Emergency Department Encounters and Hospital Admissions of People with Huntington’s Disease

    T. Orem, E. Forbes, S. Sillau (Aurora, USA)

    Objective: Define characteristics of emergency department encounters and hospital admissions of people with Huntington’s disease and identify opportunities for intervention to reduce hospitalizations. Background: Huntington’s…
  • 2025 International Congress

    Efficacy and Safety of Deutetrabenazine in Huntington’s Disease: a Systematic Review

    A. Viapiana, V. Müller, L. Lima, A. Petry, R. Juvêncio, A. Ribeiro, D. Gonçalves, M. da Rosa, G. Maia, V. Xavier (Porto Alegre, Brazil)

    Objective: To evaluate efficacy and safety of deutetrabenazine (DTB) in Huntington's Disease (HD) in order to guide evidence-based clinical decisions. Background: HD is a genetic…
  • 2025 International Congress

    Safety, Feasibility, and Effects of Time-Restricted Eating in Early-Stage Huntington’s Disease: Preliminary Analysis of a Clinical Pilot Trial

    R. Wells, L. Neilson, A. Hiller (Portland, USA)

    Objective: Evaluate whether 12 weeks of daily time-restricted eating (TRE) appears safe and feasible in persons with early-stage Huntington's disease (HD) and explore its effects…
  • 2025 International Congress

    Comparative Efficacy and Safety of VMAT2 Inhibitors for Chorea in Huntington’s Disease: A Systematic Review and Meta-Analysis

    A. Abunamoos, M. Mustafa, F. Alnajjar, Y. Aljazi, K. Moghib, N. Hamam, M. Alghaniem (Amman, Jordan)

    Objective: To assess the safety and efficacy of vesicular monoamine transporter 2 (VMAT2) inhibitors (deutetrabenazine, tetrabenazine, valbenazine) in managing chorea in Huntington’s Disease (HD). Background:…
  • 2025 International Congress

    Adult-Onset Post-Pump Chorea: A Rare Manifestation Post-Cardiac Surgery in a Puerto Rican Patient

    E. Pérez-Luciano, C. Morfi-Pagán, D. Lozada-Figueroa, L. Surillo-Dahdah (Ponce, Puerto Rico)

    Objective: To report the first case of adult-onset post-pump chorea in Puerto Rico and raise awareness of our patient’s atypical age and onset of clinical…
  • 2025 International Congress

    Unraveling NKX2-1-related disorders: clinical, genetic, and neuroimaging insights from a global cohort

    JD. Ortigoza-Escobar, L. Nou-Fontanet, C. Ravelli, S. Balsells Mejia, E. Roman Schiffels, A. Innocenti, B. Villafuerte, A. Salazar, V. Quiroz, A. Sariego Jamardo, G. Bonato, A. Díaz-Gomez, A. Afenjar, C. Vilain, P. Dumke Dasilva, D. Garcia-Navas Nuñez, M. Krygier, MJ. Molnar, L. Milanowski, K. Ounap, M. Pauni, R. Borie, P. Vega, M. Villamil, S. Yilmaz, D. Zádori, M. Zawadzka, TS. Barakat, N. Sebastian, D. Natera Debenito, L. Soliani, CM. de Gusmao, G. Garone, N. Specchio, M. Carecchio, JC. Moreno, F. Magrinelli, D. Ebrahimi-Fakhari, C. Castiglioni, M. Kurian, JN. Carvalho, R. Pons, E. Flamand-Roze, D. Doummar (Barcelona, Spain)

    Objective: To analyze the clinical spectrum, genotype-phenotype correlations, and prognostic factors in NKX2-1-related disorders (NKX2-1-RD) through a multicenter study, providing insights for improved diagnosis and…
  • 2025 International Congress

    Real-World Experiences with VMAT2 Inhibitors in Pediatric Hyperkinetic Movement Disorders

    S. Manohar, J. Jacobe, R. Berger, J. Jankovic, M. Hull (Houston, USA)

    Objective: We review the real-world prescribing practices and patient experiences with VMAT2 inhibitors in children. Background: Vesicular monoamine transporter 2 (VMAT2) inhibitors are often prescribed…
  • 2025 International Congress

    Developing a Framework for Huntington’s Disease Care Partner Training and Support – HD Care Partner Bootcamp Series

    J. Yomtoob, E. Zivin, K. Fagan, D. Bega (Chicago, USA)

    Objective: In this protocol we present a novel collaborative framework for a Huntington’s Disease (HD) Care Partner (CP) bootcamp series designed to train and support…
  • 1
  • 2
  • 3
  • …
  • 11
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley